Novartis
NVS
1,135 hedge funds and large institutions have $18.6B invested in Novartis in 2021 Q1 according to their latest regulatory filings, with 72 funds opening new positions, 417 increasing their positions, 444 reducing their positions, and 101 closing their positions.
93% more call options, than puts
Call options by funds: $239M | Put options by funds: $124M
0.38% less ownership
Funds ownership: 9.24% → 8.86% (-0.38%)
6% less repeat investments, than reductions
Existing positions increased: 417 | Existing positions reduced: 444
3% less funds holding
Funds holding: 1,176 → 1,135 (-41)
13% less capital invested
Capital invested by funds: $21.5B → $18.6B (-$2.88B)
29% less first-time investments, than exits
New positions opened: 72 | Existing positions closed: 101
71% less funds holding in top 10
Funds holding in top 10: 14 → 4 (-10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cullen Capital Management
New York
|
+$186M |
| 2 |
Goldman Sachs
New York
|
+$95.2M |
| 3 |
Parnassus Investments
San Francisco,
California
|
+$83.6M |
| 4 |
Aristotle Capital Management
Los Angeles,
California
|
+$70.9M |
| 5 |
BlackRock
New York
|
+$50M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$214M |
| 2 |
SCCM
Schafer Cullen Capital Management
New York
|
-$174M |
| 3 |
Mawer Investment Management
Calgary,
Alberta, Canada
|
-$153M |
| 4 |
ClearBridge Investments
New York
|
-$138M |
| 5 |
Primecap Management
Pasadena,
California
|
-$113M |
NVS Hedge Fund Activity: Q1 2021 in Review
1,135 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q1 2021, worth a combined $18.6B — down 13% from $21.5B a quarter earlier.
Sellers outnumbered buyers: 101 funds closed out of NVS and 72 opened new positions — a net loss of 29 holders — while 444 trimmed existing stakes and 417 added.
The largest buyer was Cullen Capital Management, adding an estimated $186M. The largest seller was Renaissance Technologies, cutting an estimated $214M.
- 1,135 institutional investors held Novartis (NVS) as of Q1 2021, down from 1,176 in Q4 2020.
- Funds reported $18.6B of Novartis stock for Q1 2021, down 13% quarter-over-quarter.
- 72 funds opened new Novartis positions in Q1 2021 and 101 closed out, a net change of -29 holders.
- The largest Novartis buyer in Q1 2021 was Cullen Capital Management, an estimated $186M added.
- The largest Novartis seller in Q1 2021 was Renaissance Technologies, an estimated $214M sold.
Based on aggregated 13F filings for Q1 2021.